SCHEMBL6470690

SCHEMBL6470690

CC(NCCO)c1ccc(N)nc1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NOS3 P29474 1/20 0.36
NOS2 P35228 1/20 0.36
EPHX2 P34913 1/20 0.36
CPB2 Q96IY4 1/20 0.35
SMN1; SMN2 Q16637 2/20 0.35
MCHR1 Q99705 1/20 0.34
CYP3A4 P08684 2/20 0.34
SLC6A4 P31645 2/20 0.34
CHRM2 P08172 1/20 0.34
HTR1A P08908 1/20 0.34
ADRA2A P08913 1/20 0.34
ADORA3 P0DMS8 1/20 0.34
CHRM1 P11229 1/20 0.34
SMPD1 P17405 1/20 0.34
DRD1 P21728 1/20 0.34
TBXA2R P21731 1/20 0.34
SLC6A2 P23975 1/20 0.34
ADRA1A P35348 1/20 0.34
OPRM1 P35372 1/20 0.34
DRD3 P35462 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5043113 0.84 HTR1A (0.41) NOS3NOS2EPHX2CPB2SMN1; SMN2
SCHEMBL5130593 0.83 CA2 (0.42) NOS3NOS2EPHX2CPB2SMN1; SMN2
SCHEMBL5040583 0.82 EPHX2 (0.36) NOS3NOS2EPHX2CPB2SMN1; SMN2
SCHEMBL5131540 0.81 KDM4E (0.38) NOS3NOS2EPHX2CPB2SMN1; SMN2
SCHEMBL23107162 0.81 FDFT1 (0.36) SMN1; SMN2MCHR1CYP3A4SLC6A4CHRM2
SCHEMBL6470688 0.79 KMT2A (0.39) SMN1; SMN2MCHR1OPRM1RAB9AKMT2A
SCHEMBL3653564 0.78 CYP3A4 (0.43) SMN1; SMN2CYP3A4SLC6A4CHRM2HTR1A
SCHEMBL5133502 0.76 KDM4E (0.36) NOS3NOS2EPHX2CPB2CYP3A4
Hydrochloric Acid SCHEMBL2934770 0.76 SMN1; SMN2 (0.44) SMN1; SMN2CYP3A4SLC6A4CHRM2HTR1A
SCHEMBL5133792 0.75 SMN1; SMN2 (0.49) EPHX2SMN1; SMN2CASRADRB2MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050107381-A1 6-membered heteroaryl compounds for the treatment of neurodegenerative disorders PFIZER, INC. 2005-05-19 US claimed
US-20050107381-A1 6-membered heteroaryl compounds for the treatment of neurodegenerative disorders PFIZER, INC. 2005-05-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050107381-A1 6-membered heteroaryl compounds for the treatment of neurodegenerative disorders APP, BACE1, SNCA NOS3 1287/4885NOS2 1936/4885EPHX2 2162/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.